Literature DB >> 25779467

Quality of Life (QoL) Assessment in Patients with Neurofibromatosis Type 2 (NF2).

Maura K Cosetti1, John G Golfinos2, J Thomas Roland3.   

Abstract

OBJECTIVE: The aim of this study was to develop a multidimensional metric for assessing quality of life (QoL) in patients with neurofibromatosis type 2 (NF2). STUDY
DESIGN: Electronically distributed questionnaire.
SETTING: University tertiary care hospital, NF2 support groups. SUBJECTS AND METHODS: Structured interviews with NF2 providers and patients identified relevant domains. Items in each domain were extracted from validated QoL modules, then combined with items unique to NF2 and pretested on NF2 providers and patients. The final 61-item questionnaire was administered electronically to patients with NF2 (N = 118). The form assessed overall QoL and 11 additional domains, including hearing, balance, facial function, vision, oral intake, future uncertainty, psychosocial, cognition, sexual activity, pain, and vocal communication. Responses were compared with reference values for the general population, patients with head and neck cancer, and patients with brain cancer.
RESULTS: Overall, QoL in patients with NF2 was lower than that of the general population (P < .01) and similar to that of patients with cancer. Patients with more facial weakness, hearing loss, and imbalance reported significantly lower QoL. However, domains most predictive of overall QoL were psychosocial, future uncertainty, and pain. Compared with patients with head and neck and brain cancer, patients with NF2 demonstrated significantly higher levels of psychosocial stressors, including disease-related anxiety, personal and financial stress, and lack of social support (P < .01).
CONCLUSION: Psychosocial stress and pain significantly affect QoL in NF2, indicating that mental health, pain management, and financial counseling could have an important impact on QoL in this population. © American Academy of Otolaryngology-Head and Neck Surgery Foundation 2015.

Entities:  

Keywords:  neurofibromatosis type 2; quality of life

Mesh:

Year:  2015        PMID: 25779467     DOI: 10.1177/0194599815573002

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  9 in total

1.  First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.

Authors:  Mojtaba Talaei-Khoei; Eric Riklin; Vanessa L Merker; Monica R Sheridan; Justin T Jordan; Scott R Plotkin; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2016-11-29       Impact factor: 4.130

2.  Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis.

Authors:  James D Doorley; Jonathan Greenberg; Jafar Bakhshaie; Nathan S Fishbein; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2021-08-19       Impact factor: 4.506

3.  Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.

Authors:  Geohana Hamoy-Jimenez; Raymond Kim; Suganth Suppiah; Gelareh Zadeh; Vera Bril; Carolina Barnett
Journal:  Neurooncol Adv       Date:  2020-01-10

Review 4.  New developments in neurofibromatosis type 2 and vestibular schwannoma.

Authors:  Yin Ren; Divya A Chari; Sasa Vasilijic; D Bradley Welling; Konstantina M Stankovic
Journal:  Neurooncol Adv       Date:  2020-11-16

5.  CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.

Authors:  Julianne Huegel; Christine T Dinh; Maria Martinelli; Olena Bracho; Rosa Rosario; Haley Hardin; Michael Estivill; Anthony Griswold; Sakir Gultekin; Xue-Zhong Liu; Cristina Fernandez-Valle
Journal:  Oncotarget       Date:  2022-07-19

6.  Auditory Brainstem Implantation for Adults With Neurofibromatosis 2 or Severe Inner Ear Abnormalities: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-03-06

7.  Association between patient-reported outcomes and objective disease indices in people with NF2.

Authors:  Aishwarya Shukla; Fang-Chi Hsu; Bronwyn Slobogean; Shannon Langmead; Yao Lu; Jaishri O Blakeley; Roy E Strowd
Journal:  Neurol Clin Pract       Date:  2019-08

8.  Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.

Authors:  Heather L Thompson; Ann Blanton; Barbara Franklin; Vanessa L Merker; Kevin H Franck; D Bradley Welling
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

9.  Prevalence of oral neurofibroma in Central Indian population: A retrospective study of 20 years.

Authors:  Suchitra R Gosavi; Riya S Jain; Abhay Datarkar
Journal:  J Oral Maxillofac Pathol       Date:  2021-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.